BMY is presently in a wedge. Though a breakdown is certainly possible over the next decade, what are reasonable breakout levels to watch? This chart with Fib levels induced by the move from all-time lows to all-time highs gives some clues. Approximately $75 is first up, then approximately $120.
Humanigen's stock has two lower trend resistance lines with price targets of $3 and $2, respectively. The first resistance line has just hit after a month of major events. Catalyst 1: Marc Bistricer of Murchison and Nomis Bay bought back in after major selling over the past year. Catalyst 2: 7 corporate insiders including the CEO (Cameron Durrant) and Chief...
Q3 2021 results warrant a re-rating of this $30M mkt cap biotech play: - Revenue was $25.3 million in the third quarter of 2021, up 575%, compared to $3.7 million over the prior three-month period ending June 30, 2021. - Gross profit was $10.5 million in the third quarter of 2021, up 1,288%, compared to $753,535 over the prior three-month period ending June 30,...
Note: ER 11/30 Tues Roth Capital analyst Jonathan Aschoff initiated coverage of BFRI stock with a buy rating and $20 price target. The analyst believes the stock is poised for growth thanks to its U.S. sales plans. Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States....
Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red...
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic...
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various...
Strong support line on 122.12$. Firs target on 160$, second - 206$. Stop Limit on 118$. P/L ratio 1:1 for firs target & 3:1.
- $19M mkt cap / 11M float - $28.4M cash eq. - $17.1M Q3 revenue / $7M adjusted EBITDA - Options at $3.27 - Warrants at $3.53 - Enterprise value (as of Sep 30, 2021): $103.8M!! - Canadian Commercial business is focused on Pain, Neurology, Allergy, And Dermatology therapeutics. - 17 Global Distribution Partners across 31 Countries. - Over 100 global patents and...
Easy & risky trade Price target as shown on the graph Loss is 5% Gain is 40% and above Does it worth a try! Think about it and trade safe
This one is almost pure intuition. We're in pharmaceuticals earnings season now. Seagen reports after market today. A bunch of other large holdings of XBI report on November 3-4, and a bunch more on November 8. Bonds and tech stocks have made a breakout move upward, and small caps look primed. (XBI is full of small and micro caps.) XBI has had a long consolidation...
looks like the 5 down are about finished. Would want to see an ABC correction 1st then 5 up impulsive move B4 I could make any targets.
Looks like a push to the 618 fib retracement might be up next. If we have an impulsive 5 up incoming the chart should look like this IMO.
All, I am already scaled in big here. I am without a doubt this stock will at least double. ***KEEP IN MIND THIS IS AN 8M FLOAT COMPANY 1. Do your own DD you will notice all that has really happened is low float short sellers have just railed the price down 2. This companies price targets are insane not to mention 8M float will make this EXPLODE on any good...
Appears to have bottomed here and corrections are zig zig patterns 5,3,5 that continue to overlap into each other so I labeled this correction with WXY. Most likely TTOO will push back up from here towards $1.40
Beyond Air has continued a strong uptrend since June. Recently its bin tapering and has shown a symmetrical triangle formation. A Brake out to the upside is likely to continue the uptrend. Watch for a move past the top of the triangle at 11.88 level for conformation and more possible upside. No resistance till 12.50 a high not seen since March 4, 2020
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low...
bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees,...